The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of a two-protein panel PMS2/MSH6 for detecting mismatch repair deficiency in endometrial cancer: A single institution study.
 
Danielle Glassman
No Relationships to Disclose
 
Jessica Velasquez
No Relationships to Disclose
 
Paulina Haight
No Relationships to Disclose
 
Marie-Veronique Poirier
No Relationships to Disclose
 
Sadie Longo
No Relationships to Disclose
 
Courtney Riedinger
No Relationships to Disclose
 
Adrian Suarez
No Relationships to Disclose
 
Ashwini Esnakula
No Relationships to Disclose
 
Laura Chambers
No Relationships to Disclose
 
Christa Nagel
No Relationships to Disclose
 
Larry Copeland
Leadership - GOG Foundation
Consulting or Advisory Role - Abbvie; GOG Foundation
 
David Cohn
Research Funding - AbbVie (Inst); Advaxis (Inst); Agenus (Inst); Ajinomoto (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Henry Jackson Foundation (Inst); ImmunoGen (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen Research & Development (Inst); Ludwig Institute for Cancer Research (Inst); Novartis (Inst); NRG Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); PRA International (Inst); Regeneron (Inst); Sanofi (Inst); Stemcentrix (Inst); Tesaro (Inst); Tricon Pharmaceuticals (Inst)
Other Relationship - Elsevier; UpToDate
 
Floor Backes
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); biontech; Daiichi Sankyo/Astra Zeneca; Eisai; EMD Serono; GlaxoSmithKline; Immunogen; Immunogen (Inst); Merck; Merck (Inst); natera (Inst)
Research Funding - Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate (for writing a chapter)
 
David O'Malley
Consulting or Advisory Role - Abbvie; AstraZeneca; Corcept Therapeutics; DualityBio; GlaxoSmithKline; GOG Foundation; Merck; Novocure; Novocure; Pfizer; Regeneron; Sutro Biopharma; Verastem; Zentalis
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst); Zentalis (Inst)
 
Casey Cosgrove
Honoraria - GOG Foundation; Immunogen; UpToDate
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Imvax; Intuitive Surgical
Research Funding - GlaxoSmithKline; Regeneron